Of the 4 DLBCL patients, 3 were treated with polatuzumab vedotin with bendamustine plus rituximab (pola+BR) and 1 with polatuzumab vedotin with bendamustine plus obinutuzumab (pola+BG). The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.